ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022

ADMA Biologics, Inc. (Nasdaq: ADMA) will announce its Q1 2022 financial results on May 11, 2022, after market close.

Rhea-AI Summary

ADMA Biologics, Inc. (Nasdaq: ADMA) will announce its Q1 2022 financial results on May 11, 2022, after market close. A live conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results and other company updates. ADMA specializes in plasma-derived biologics aimed at immunodeficient patients and currently markets three FDA-approved products: ASCENIV™, BIVIGAM®, and NABI-HB®. The company operates from its Boca Raton, Florida facility and maintains FDA approval for its processes and products.

Argus Session date unavailable

+2.06% session move Open Argus

Details

News Market Reaction – ADMA

The recorded move for ADMA in the trading session of this news was +2.06%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference Call Scheduled for May 11, 2022 at 4:30 p.m. ET

RAMSEY, N.J. and BOCA RATON, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the first quarter ended March 31, 2022 on Wednesday, May 11, 2022, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.

To access the conference call, please dial (855) 884-8773 (local) or (615) 622-8043 (international) at least 10 minutes prior to the start time and refer to conference ID 1783606. A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM^® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB^® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 and European Patent No. 3375789 related to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

COMPANY CONTACT:
Skyler Bloom
Senior Director, Business Development & Corporate Strategy | 201-478-5552 |
sbloom@admabio.com

INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com

 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will ADMA Biologics report Q1 2022 financial results?

ADMA Biologics will report its Q1 2022 financial results on May 11, 2022, after the market closes.

What time is the ADMA Biologics conference call scheduled?

The conference call is scheduled for May 11, 2022, at 4:30 p.m. ET.

How can I access the ADMA conference call?

You can access the conference call by dialing (855) 884-8773 locally or (615) 622-8043 internationally, or by visiting the investor section of ADMA's website for the audio webcast.

What products does ADMA Biologics manufacture?

ADMA Biologics manufactures three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM®, and NABI-HB®.

Where does ADMA Biologics manufacture its products?

ADMA Biologics manufactures its products at an FDA-licensed facility in Boca Raton, Florida.